Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer
Population
8 patients aged 22 to 67 years who died during or within 4 days of interleukin-2 based immunotherapy for…
Design
Case_series
Follow-up
during or within 4 days of therapy
Authors
Discussion
Loading...
Member takes
Implication
IL-2 may cause fatal cardiac events; leaves open whether monitoring improves outcomes in cancer patients.
Structured PICO
P
Population
8 patients aged 22 to 67 years (mean, 41 years) who died during or within 4 days of interleukin-2 (IL-2) based immunotherapy for treatment of renal cell carcinoma or melanoma
I
Intervention
Interleukin-2 (IL-2) based immunotherapy
O
Outcome
Cardiac necropsy findings (cause of death and myocardial pathology)safety
IL-2 therapy for cancer can be associated with fatal noninfectious myocarditis or acute myocardial infarction, highlighting the need for careful cardiac monitoring.
Cite This Study
Kragel et al. (1990) studied this question.